Herrmann, Ken
National Center for Tumor Diseases · University of Duisburg-Essen
2 papers on CoChat
Most cited papers
- Verified
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 362
- Verified
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 125
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free